Gilead Sciences, Inc. revenue by segment GILD

Annual Quarterly

Gilead Sciences, Inc. splits its revenue into 32 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was HIV Product Sales at $20.8 billion, 70% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	30,988	29,443	28,754	27,116	27,281	27,305	24,689	22,449	22,127	26,107	30,390
HIV Product Sales	22,772 +11.6% share 73.5%	20,752 share 70.5%	—	—	—	—	16,938 +3.0% share 68.6%	16,438 share 73.2%	—	—	—
HIV Products Descovy	—	—	2,113 share 7.3%	—	—	—	—	—	—	—	—
HCV Product Sales	—	—	—	—	—	—	2,064 share 8.4%	—	—	—	—
Other Products Yescarta	1,341 -11.5% share 4.3%	1,495 share 5.1%	—	—	—	—	—	—	264 +3671.4% share 1.2%	7 share 0.0%	—
Trodelvy	1,748 +27.8% share 5.6%	1,397 share 4.7%	—	—	—	—	49 share 0.2%	—	—	—	—
Liver Disease Products Sofosbuvir Velpatasvir	1,136 -14.3% share 3.7%	1,272 -20.3% share 4.3%	1,596 share 5.6%	—	—	—	—	—	—	—	—
HIV Products Odefsey	1,057 -11.4% share 3.4%	1,167 -9.4% share 4.0%	1,288 share 4.5%	—	—	—	—	—	—	1,106 share 4.2%	—
Liver Disease Products Vemlidy	1,147 +10.0% share 3.7%	1,070 +11.6% share 3.6%	959 share 3.3%	—	—	—	—	—	—	—	—
Hepatitis B Virus Hepatitis Delta Virus Product	—	—	—	—	988 +2.0% share 3.6%	969 share 3.5%	—	—	—	—	—
Veklury	464 -55.3% share 1.5%	911 -49.4% share 3.1%	1,799 share 6.3%	—	—	—	—	—	—	—	—
Liver Disease Products Other Liver Disease	853 +70.6% share 2.8%	874 +87.2% share 3.0%	467 share 1.6%	—	—	—	—	—	—	—	—
Other Products Total Other Product Sales	—	—	—	859 -9.2% share 3.2%	946 share 3.5%	—	—	—	—	—	—
Royalty Contract And Other	223 -58.6% share 0.7%	527 +266.0% share 1.8%	144 -20.9% share 0.5%	182 share 0.7%	—	—	—	—	450 +1.1% share 2.0%	445 share 1.7%	—
Other Products Am Bisome	465 -7.0% share 1.5%	509 -4.5% share 1.7%	533 share 1.9%	—	—	—	—	—	420 +14.8% share 1.9%	366 share 1.4%	—
HIV Products Other HIV	455 +23.6% share 1.5%	500 +15.2% share 1.7%	434 share 1.5%	—	—	—	—	—	—	—	—
HIV Products Symtuza Revenue Share	540 +6.7% share 1.7%	495 -16.4% share 1.7%	592 share 2.1%	—	—	—	—	—	79 share 0.4%	—	—
Cell Therapy Products Tecartus	296 -15.9% share 1.0%	344 -14.6% share 1.2%	403 share 1.4%	—	—	176 +300.0% share 0.6%	44 share 0.2%	—	—	—	—
Hepatitis B Virus Hepatitis Delta Virus Product Vemlidy	—	—	—	—	—	—	—	—	321 +163.1% share 1.5%	122 share 0.5%	—
Other Products Other	263 -5.7% share 0.8%	290 -18.5% share 1.0%	356 share 1.2%	—	—	—	—	203 -36.6% share 0.9%	320 share 1.4%	—	—
HCV Products Vosevi	—	—	—	—	—	—	—	257 share 1.1%	—	293 share 1.1%	—
HIV Products Complera Eviplera	—	—	—	—	200 share 0.7%	—	—	—	653 share 3.0%	—	—
Other Products Letairis	—	—	—	—	196 share 0.7%	—	—	—	943 share 4.3%	—	—
Other HCV	—	—	—	160 -3.6% share 0.6%	166 share 0.6%	—	—	328 share 1.5%	—	—	—
HIV Products Atripla	—	—	—	—	—	145 share 0.5%	—	600 share 2.7%	—	—	—
HIV Products Truvada	—	—	—	114 share 0.4%	—	—	—	—	—	—	—
HIV Products Stribild	—	—	—	101 -20.5% share 0.4%	127 share 0.5%	—	—	369 share 1.6%	—	—	—
Hepatitis B Virus Hepatitis Delta Virus Product Viread	—	—	—	83 -8.8% share 0.3%	91 -18.0% share 0.3%	111 -40.0% share 0.4%	185 -23.9% share 0.7%	243 -20.8% share 1.1%	307 share 1.4%	—	—
Hepatitis B Virus Hepatitis Delta Virus Product Other	—	—	—	72 +30.9% share 0.3%	55 +25.0% share 0.2%	44 +144.4% share 0.2%	18 +63.6% share 0.1%	11 share 0.0%	—	—	—
HCV Products Ledipasvir Sofosbuvir	—	—	—	70 -39.1% share 0.3%	115 -45.8% share 0.4%	212 -22.1% share 0.8%	272 share 1.1%	—	—	—	—
Other Products Zydelig	—	—	—	—	—	62 share 0.2%	—	103 -22.6% share 0.5%	133 -10.7% share 0.6%	149 share 0.6%	—
Products Other HIV	—	—	—	56 -1.8% share 0.2%	57 -70.8% share 0.2%	195 share 0.7%	—	47 -23.0% share 0.2%	61 +5.2% share 0.3%	58 share 0.2%	—
Other Products Ranexa	—	—	—	—	—	10 +11.1% share 0.0%	9 -95.8% share 0.0%	216 share 1.0%	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: GILD (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Foster City, CA
SEC filer status: Large accelerated filer
SEC CIK: 882095
Former names: GILEAD SCIENCES INC (until Feb 17, 2022)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.